INVESTORS

AT A GLANCE

"A pioneer of digital therapeutics, Voluntis was the first such company to go public. Personally, and in the name of the entire Voluntis team, I would like to thank all of our new and historic shareholders for their faith in us. This investment of €30.1M will allow us to continue our commitment to patients and healthcare professionals, helping them better manage treatment in the hopes that this improves real-world efficacy." - Pierre Leurent, CEO of Voluntis

STOCK INFORMATION

EURONEXT Paris

WHAT'S NEW

Upcoming events

2020 H1 Results

NEWS

Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins

PRESS RELEASES

DOCUMENTS

No documents match your search. Please choose different criteria.

CONTACT THE INVESTOR RELATIONS TEAM




Tel:
Email: voluntis@actus.fr